文献速递心外重症与机械循环支持

心室辅助装置患者卒中与死亡风险因ISHLT感染分类而异:INTERMACS分析

Stroke and death risk in ventricular assist device patients varies by ISHLT infection category: An INTERMACS analysis.
PubMed 文献 · J Heart Lung Transplant · 2019-02-12

基于INTERMACS注册的16,597例连续流心室辅助装置(VAD)患者,按ISHLT感染分类分析显示,42%患者发生感染,其中非VAD感染占49%、VAD相关感染占26%、VAD特异性感染占25%。感染患者卒中患病率高于无感染者(18% vs 11%,p<0.001),且VAD相关感染后出血性卒中发生率最高(0.13 EPPY),VAD特异性感染后1年生存率最高(87%)。

要点

  • VAD感染按ISHLT分类可区分卒中与死亡风险差异
  • VAD相关感染后出血性卒中发生率最高(0.13 EPPY)
  • VAD特异性感染后1年生存率87%,高于其他感染类型

核心结论

  • ISHLT的VAD感染分类揭示了卒中与死亡风险的显著差异。
  • 对符合条件的感染VAD患者重新评估移植优先顺序可能有助于提高移植相关生存获益。

研究设计与样本

  • 查询INTERMACS注册数据库,识别16,597例连续流VAD接受者。
  • 在多变量模型中检验感染分类以确定卒中和死亡风险。

主要发现

  • 植入后7,046例患者(42%)发生感染,中位时间69天(四分位距12至272天)。
  • 感染类型分布:非VAD感染49%、VAD相关感染26%、VAD特异性感染25%。
  • VAD相关感染中血流感染(BSI)最常见(92%),其中多数(59%)为无相关感染的特发性菌血症。
  • 内部泵组件感染罕见(0.003事件/患者年[EPPY])。
  • 感染VAD患者卒中患病率高于无感染者(18% vs 11%,p<0.001)。

关键数值与推荐

  • VAD特异性感染后卒中率最低(0.11 EPPY),低于VAD相关感染(0.17 EPPY)和非VAD感染(0.15 EPPY,p<0.001)。
  • 所有感染组中出血性卒中均多于缺血性卒中,VAD相关感染后最高(0.13 EPPY)。
  • 感染后1年生存率:VAD特异性感染87%,VAD相关感染71%,非VAD感染72%(p<0.001)。

临床怎么用

  • 临床应按照ISHLT分类识别VAD感染类型以分层评估卒中和死亡风险。
  • 对感染VAD患者,尤其VAD相关感染,需警惕出血性卒中风险。
  • 对 eligible 感染VAD患者可考虑重新评估移植优先顺序以改善生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ventricular assist device (VAD) patients often experience infections, which increase the risk of stroke and mortality. Using the definitions of the International Society for Heart and Lung Transplantation (ISHLT), we have characterized differences in clinical outcomes for categories of infection: VAD-specific (e.g., pump component related); VAD-related (e.g., bloodstream infection, BSI); and non-VAD infections (e.g., pneumonia). METHODS: Querying of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) identified 16,597 continuous-flow VAD recipients. Categories of infection were tested in multivariate models to determine the risk of stroke and death. RESULTS: After implant, 7,046 patients (42%) developed an infection at a median of 69 (interquartile range 12 to 272) days. A majority were non-VAD infections (49%), followed by VAD-related (26%) and VAD-specific infections (25%). BSIs were the most common form of VAD-related infection (92%), and the majority (59%) had no associated infection, that is, idiopathic bacteremia. Internal pump component infections were rare (0.003 event per patient-year [EPPY]). Infected VAD patients had a higher prevalence of stroke compared to patients without an infection (18% vs 11%, p < 0.001). The lowest stroke rate occurred after a VAD-specific infection (0.11 EPPY) compared with VAD-related (0.17 EPPY) and non-VAD infections (0.15 EPPY, p < 0.001). Hemorrhagic strokes were more common than ischemic strokes in all infection groups and highest after a VAD-related infection (0.13 EPPY). One-year survival after an infection was 87% in VAD-specific infections, as compared with VAD-related (71%) and non-VAD infections (72%, p < 0.001). CONCLUSIONS: The ISHLT categorization of VAD infections unveils notable differences in associated risk of stroke and mortality. A re-assessment of transplant prioritization for eligible infected VAD patients may be useful to increase transplant-related survival benefit.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Shah P, Birk SE, Cooper LB, et al. Stroke and death risk in ventricular assist device patients varies by ISHLT infection category: An INTERMACS analysis. J Heart Lung Transplant. 2019. PMID: 30954340. doi:10.1016/j.healun.2019.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。